Scancell Holdings Plc PDMR Notification (9067V)
06 December 2023 - 11:41PM
UK Regulatory
TIDMSCLP
RNS Number : 9067V
Scancell Holdings Plc
06 December 2023
6 December 2023
Scancell Holdings plc
("Scancell" or the "Company")
PDMR Notification
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
announces that further to the Company's announcement on the 1
December 2023 regarding the successful placing of ordinary shares
of nominal value of 0.1 pence in the Company ("Shares") and the
subscription for Shares by Dr Jean-Michel Cosséry and Professor
Lindy Durrant, the following Shares were issued on 5 December
2023:
Dr Jean-Michel Cosséry 454,545
Professor Lindy Durrant 272,727
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH
THEM
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Jean-Michel Cosséry
------------------------------- ---------------------------------------------
Reason for the notification
2
------------------------------------------------------------------------------
a) Position/status Chairman of Board and PDMR
------------------------------- ---------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ---------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Scancell Holdings plc
------------------------------- ---------------------------------------------
b) LEI 2138008RXEG856SNP666
------------------------------- ---------------------------------------------
Details of the transaction(s): section to be repeated for (i)
4 each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
------------------------------------------------------------------------------
a) Description of the Ordinary shares
financial instrument,
type of instrument
------------------------------- ---------------------------------------------
b) Identification Code GB00B63D3314
------------------------------- ---------------------------------------------
c) Nature of the transaction Acquisition of ordinary shares
------------------------------- ---------------------------------------------
d) Price(s) and volume(s) 454,545 ordinary shares at GBP0.11 per share
------------------------------- ---------------------------------------------
e) Aggregated information
- Aggregated volume N/A (single transaction)
- Price
------------------------------- ---------------------------------------------
f) Date of the transaction 5 December 2023
------------------------------- ---------------------------------------------
g) Place of the transaction Outside a trading venue
------------------------------- ---------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Lindy Durant
------------------------------- ---------------------------------------------
Reason for the notification
2
------------------------------------------------------------------------------
a) Position/status Executive Director and PDMR
------------------------------- ---------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ---------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Scancell Holdings plc
------------------------------- ---------------------------------------------
b) LEI 2138008RXEG856SNP666
------------------------------- ---------------------------------------------
Details of the transaction(s): section to be repeated for (i)
4 each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
------------------------------------------------------------------------------
a) Description of the Acquisition of ordinary shares
financial instrument,
type of instrument
------------------------------- ---------------------------------------------
b) Identification Code GB00B63D3314
------------------------------- ---------------------------------------------
c) Nature of the transaction Acquisition of ordinary shares
------------------------------- ---------------------------------------------
d) Price(s) and volume(s) 272,727 ordinary shares at GBP0.11 per share
------------------------------- ---------------------------------------------
e) Aggregated information
- Aggregated volume N/A (single transaction)
- Price
------------------------------- ---------------------------------------------
f) Date of the transaction 5 December 2023
------------------------------- ---------------------------------------------
g) Place of the transaction Outside a trading venue
------------------------------- ---------------------------------------------
-ENDS-
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3709 5700
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser
and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium +44 (0) 20 3709 5700
Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHTFBTTMTJMBPJ
(END) Dow Jones Newswires
December 06, 2023 07:41 ET (12:41 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024
